NGFR and melanoma: When tumor biopsies from drug‐naïve melanoma patients were immunostained for NGFR, we observed variability from one tumor to the next and, within a single tumor, from one region to the next: NGFRHigh/MITFLow and NGFRLow/MITFHigh domains were present in 4/11 samples and the former stained less strongly for Ki‐67 (Fig 10A and Appendix Fig S8).